AI Analysis
AI-generated analysis. Always verify with the original filing.
Aptorum Group Limited filed a Form 6-K providing a proxy statement/prospectus for a proposed merger with DiamiR Biosciences Corp., where DiamiR shareholders will own approximately 70% of the combined company.
Key Takeaways
1Aptorum and DiamiR entered into a merger agreement on July 14, 2025, with DiamiR shareholders expected to own ~70% of the combined company post-closing.
2Aptorum reported a net loss of $1.37 million for the year ended December 31, 2025, with negative working capital of $1.0 million and an accumulated deficit of $73.8 million.
3The company raised approximately $1.72 million in net proceeds from an October 2025 offering of Class A ordinary shares and warrants.
4Aptorum faces a lawsuit filed in September 2024 alleging RICO violations and fraud; the company believes the claims have no merit.
5The merger termination date was extended to June 30, 2026, with Aptorum pausing the majority of its R&D activities to focus on the transaction.